SPECIAL FEATURES

CCR Translations

323  BAP1tism of a Tumor Suppressor
Scott E. Woodman
See article p. 408

Molecular Pathways

326  Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
William C. Dougall

Perspective

336  New Challenges in Endpoints for Drug Development in Advanced Melanoma
Antoni Ribas, Peter Hersey, Mark R. Middleton, Helen Gogas, Keith T. Flaherty, Vernon K. Sondak, and John M. Kirkwood

Review

342  Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Michaela R. Reagan and Irene M. Ghobrial

HUMAN CANCER BIOLOGY

350  Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
Brooke E. Sylvester, Dezheng Huo, Andrey Khramtsov, Jing Zhang, Rana V. Smalling, Sope Olugbile, Blase N. Polite, and Olufunmilayo I. Olopade

359  A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
Rajasubramaniam Shanmugam, Padmaja Gade, Anique Wilson-Weekes, Hamid Sayar, Attaya Suwanpansakha, Chirayu Goswami, Lang Li, Sushil Gupta, Angelo A. Cardoso, Tareq Al Baghdadi, Katie J. Sargent, Larry D. Cripe, Dhananjaya V. Kalvakolanu, and H. Scott Boswell

369  Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
Rossitza Lazova, Robert L. Camp, Vincent Klump, Summar F. Siddiqui, Ravi K. Amaravadi, and John M. Pawelek

379  Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Hsiu-Fung Yuen, Ka-Xiu Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osama Sharaf Eldin, Ken O’Byrne, Pasi Janne, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, and Mohamed El-Tanani

389  Serum Interleukin-6, Insulin, and HOMA-IR in Male Individuals with Colorectal Adenoma
Yu Sasaki, Hiroaki Takeda, Takeshi Sato, Tomohiko Oti, Shouichi Nishise, Ko Naqino, Daisuke Iwano, Takao Yoita, Kazuya Yoshizawa, Hideki Saito, Yasuhisa Tanaka, and Sumio Kawata

399  Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
Min-Han Tan, Jessica L. Mester, Joanne Ngeow, Lisa A. Rybicki, Mohammed S. Orloff, and Charis Eng

CANCER THERAPY: PRECLINICAL

408  Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Solange Landreville, Olga A. Agapova, Katie A. Matatall, Zachary T. Kneass, Michael D. Onken, Ryan S. Lee, Anne M. Bowcock, and J. William Harbour
See commentary p. 323

418  Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells
Sascha Dietrich, Oliver H. Kramer, Esther Hahn, Claudia Schäfer, Thomas Giese, Michael Hess, Theresa Tretter, Michael Rieger, Jennifer Hüllein, Thorsten Zenz, Anthony D. Ho, Peter Dregger, and Thomas Luft
Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma


Bexarotene via CBP/p300 Induces Suppression of NF-κB-Dependent Cell Growth and Invasion in Thyroid Cancer

Audrey Cras, Beatrice Politiis, Nicole Balitrand, Diane Darsin-Bettinger, Pierre Yves Boelle, Bruno Cassinat, Marie-Elisabeth Toubert, and Christine Chomienne

Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth

Andreas Wicki, Christoph Bachlitz, Annette Orleth, Reto Ritschard, Enke Albrecht, Richard Herrmann, Gerhard Christofori, and Christoph Mamot

EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells

Michele Cioffi, Jorge Dorado, Patrick A. Baueuerle, and Christopher Heeschen

CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells

Daniela Trisciuoglio, Ylenia Ragazzoni, Andrea Pelosi, Marianna Desideri, Simone Carradori, Chiara Gabellini, Giovanna Maresca, Riccardo Nescaletti, Daniela Secchi, Adriana Bolasco, Bruna Bizzarri, Chiara Cavallere, Igra D’Agnano, Patrizia Filetici, Lucia Ricci-Vitiani, Maria Giulia Rizzo, and Donatella Del Bufalo

Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia


VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

Hailing Lu, Gregory N. Dietsch, Maura-Ann H. Matthews, Yi Yang, Smita Ghanekar, Margaret Inokuma, Maria Suni, Vernon C. Maino, Katherine E. Henderson, James Jeffry Howbert, Mary L. Disis, and Robert M. Hershberg

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty, Patricia M. LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia S. Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O'Dwyer, and Gary K. Schwartz

A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303

Gene Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non–Small Cell Lung Cancer Patients
Klaus W. Wagner, Yuanqing Ye, Jie Lin, Ara A. Vaporciyan, Jack A. Roth, and Xifeng Wu

ABOUT THE COVER

Although antiangiogenic therapies are effective and comparatively safe treatments against human cancer, renal toxicity is one of the major concerns. Anti-VEGFR2 immunoliposomes loaded with a chemotherapeutic drug showed marked antitumor activity in various tumor models. Importantly, no long-term renal side effects were evident with this therapy. This image shows a section of mouse kidneys 18 months after repeated injection of anti-VEGFR2 immunoliposomes loaded with doxorubicin. For details, see the article by Wicki and colleagues on page 454 of this issue.